Navigation Links
Fenwick & West Life Science Venture Financing Survey Shows Mild Improvement in Valuations Amid Overall Difficult Financing Environment
Date:9/11/2012

MOUNTAIN VIEW, Calif., Sept. 11, 2012 /PRNewswire/ -- Fenwick & West LLP, one of the nation's premier law firms providing comprehensive legal services to high technology and life science clients, today announced the results of its First Half 2012 Life Science Venture Capital Survey.

The First Half 2012 Survey analyzes the valuations and terms of venture financings for 186 life science companies headquartered in the United States that reported raising capital during the first half of 2012.

"For the first half of 2012, up rounds outpaced down rounds 53% to 19%, with 28% flat. This is a modest improvement over results from 2011, which averaged 47% up rounds and 25% down rounds, with 28% flat," said Matt Rossiter, a partner in the firm and co-author of the survey.

An up round is one in which the price per share at which a company sells its stock has increased since its prior financing round. Conversely, a down round is one in which the price per share has declined since a company's prior financing round.

The Fenwick & West Life Science Venture Capital Barometer™ – which measures the change in share price of life science companies funded during the year compared with the share price of their previous financing round – showed average price increases of 19% and 26% for Q1 and Q2 of 2012, in comparison to average price increases of 4% and 11% for Q1 and Q2 of 2011. 

"The Barometer results have continued to trend upward during 2012," said Rossiter. "This is a positive sign, and suggests that startups are continuing to develop promising technologies that can justify a step up in valuation. However, it is important to keep in mind that fewer life science financings are occurring, and the Life Science Barometer results continue to trail results for other industries covered by our Silicon Valley Venture Capital Survey."    

"The life science venture financing environment remains challenging," noted Barry Kramer, survey co-author and also a partner at the firm, "with investment into venture-backed life science companies falling off significantly from 2011, and fundraising by life science-focused investors also decreasing.  A potential bright spot, however, is that we are seeing some increased involvement by large life science companies in the venture funding process. This makes sense, as large pharmaceutical and medical device companies need a healthy life science start up industry to help fill their product pipelines, and with weakness in the venture side of the industry, it is both an opportunity, and maybe even a necessity, for the larger companies to become more involved with the start up environment."

Complete results of the survey with related discussion are posted on Fenwick & West's website at fenwick.com/lifesciencesurvey.

About the Survey

The Fenwick & West Life Science Venture Capital Survey, co-authored by law firm partners Matt Rossiter, Barry Kramer and Michael Patrick, offers a unique view of the life science venture capital market by providing insight into the changes in venture capital valuations and terms. By focusing on these trends, the Fenwick & West Survey complements the data reported by other industry sources, such as Dow Jones VentureSource and the MoneyTree™ Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.

About Fenwick & West

Established in 1972, Fenwick & West LLP is one of the nation's premier law firms with extensive expertise in venture capital, public offerings and other corporate finance, joint ventures, M&A and strategic relationships, intellectual property, litigation and dispute resolution, taxation, antitrust and employment and labor law.

Contacts:

Matt Rossiter
Fenwick & West LLP
Phone: 415.875.2372
Email: mrossiter@fenwick.com

Barry Kramer
Fenwick & West LLP
Phone: 650.335.7278
Email: bkramer@fenwick.com

Jennifer Shanks
Le@p! Public Relations
Phone:  408.827.8033
Email:  jennifer@leappr.com


'/>"/>
SOURCE Fenwick & West LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):